Retrospective analysis on adverse drug reactions of four PD-1 inhibi-tors reported in literature
10.12092/j.issn.1009-2501.2024.08.006
- VernacularTitle:4款国产PD-1抑制剂不良反应文献回顾性分析
- Author:
Xiao YU
1
,
2
;
Yan ZHOU
;
Qin LI
;
Xuefang CHENG
Author Information
1. 上海交通大学医学院附属第一人民医院临床药学科,上海 200080
2. 郯城县第一人民医院药剂科,临沂 276100,山东
- Keywords:
adverse drug reactions;
PD-1 inhibi-tors;
camrelizumab;
sintilimab;
toripalimab;
tisleli-zumab
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(8):887-898
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To analyze the occurrence and clinical characteristics of adverse drug reactions(ADR)induced by four programmed cell death pro-tein 1(PD-1)inhibitors according to literature re-ports,and to provide reference for clinical safe medication.METHODS:PubMed,CNKI,and Wan-fang,and other databases were searched to collect case reports of adverse reactions caused by four PD-1 inhibitors,including camrelizumab,sintilimab,toripalimab,and tislelizumab.RESULTS:A total of 105 eligible literature reports were retrieved from the databases at home and abroad(as of June 1,2022),including 42 reports on camrelizumab with 47 patients,29 reports on sintilimab with 30 pa-tients,21 reports on toripalimab with 24 patients and 13 reports on tislelizumab with 15 patients.Among them,there were 76 males(65.5％)and 40 females(34.5％),with a gender ratio of 1.9:1.0.The age range was between 29 to 84 years old,and the onset of ADR mainly occurred within 4 months af-ter the first use of PD-1 inhibitors.Immune-related adverse reactions were mainly manifested as skin and its attachment(41 cases,34.5％),endocrine sys-tem(25 cases,21.0％),and cardiovascular system(22 cases,18.5％).Most patients improved after symptomatic and supportive treatment.CONCLU-SION:Immune-related adverse effects(irAEs)may occur at any time during treatment with the four PD-1 inhibitors,among these the skin system is most frequently affected,followed by the cardiovas-cular and endocrine systems.This suggests the im-portance of individualized drug administration and stringent control over indications in clinical prac-tice.Close monitoring throughout immunotherapy is essential to minimize or prevent irAEs,thus en-suring patient safety in medication usage.
